
The U.S. government is funding a $375 million effort for a new COVID-19 prevention drug for immunocompromised people, as part of Project NextGen. The federal health department provided the funds to the drug company Shionogi Inc. for a long-acting pre-exposure prophylactic (PreP) called S-892216 that blocks the main protease of SARS-CoV-2.


*Editor’s note: Julia Moore Vogel, an author of Paxlovid study, is on The Sick Times’ advisory board. Other authors are also affiliated with the Patient-Led Research Collaborative, which shares a funding source (the Balvi and Kanro funds) with The Sick Times. One author (JD Davids) is affiliated with Long COVID Justice, with which we collaborated…

A 2020 paper that spread controversial claims about the anti-malarial drug hydroxychloroquine as a treatment for COVID-19 was retracted last week. Published in the International Journal of Antimicrobial Agents, the paper was pulled for ethical concerns and other methodological problems. Earlier in the pandemic, the paper led to shortages of the drug for people with…

Editor’s note, December 19, 11am EST: The fourth summary has been updated to correct information about the patients who were autopsied. Related stories

The U.S. National Institutes of Health (NIH) has announced further funding for its flagship Long COVID research program, called RECOVER, as well as new details about the program’s budget through 2029. RECOVER will receive an additional $147 million, building on $515 million allocated earlier this year and the original $1.15 billion funded by Congress in…









advocacy arts CDC clinical trials commentary COVID-19 precautions disability essay government policy H5N1 healthcare HHS influenza international Long COVID in children masks and respirators ME ME/CFS medical education national COVID-19 trends NIH NIH RECOVER podcast public health research update science Trump administration updates and events vaccines wastewater surveillance